Vir Biotechnology stock
VIRNASDAQVir Biotechnology, Inc., HealthcareISIN US92764N1028
52Score 52 out of 100, Neutral
Price and trend
86 / 100
Price history
+112% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 24% above it.
Since December 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 60).
The price is 11% below its 52-week high. Largest decline in 7 years: 95% (January 2021 to August 2025).
Chart figures for advanced users
- SMA 50$11.18
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.75
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)60
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.44
- The lowest closing price of the last twelve months.
- Resistance$13.65
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Vir Biotechnology, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $2.08B, is number 122 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $68.56M (down 7.6% year on year) and a loss of $437.99M.
- MEQIRI Score 52 out of 100 (Neutral): rank 373 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $458.36M, financial debt $90.78M.Stability 70
Weaknesses
- Loss-makingLoss of $184.79M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$136.99M over the last 12 months.Fundamentals 17
- DilutionShare count up 16% since 2020.Capital allocation 18
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 7.6% on the prior year. Revenue has grown strongly since 2017, at around 50% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 83%, operating −683%, net −639%. Last 12 months: net −61%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 22 Feb 2027in 102 days
- Last reported
- 4 Nov 2026EPS reported −$0.57 (expected −$0.77)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.78−0.6%
- Revenue
- $246.03M+0.3%
- Earnings per share
- −$2.54+0.3%
- Revenue
- $73.41M−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −4.4%No financial guidance: hepatitis delta trial data are expected in the fourth quarter of 2026 and the first quarter of 2027, with the larger manufacturing costs behind the company.
“With enrollment now complete across all 3 registrational ECLIPSE studies, we are entering a catalyst-rich period for hepatitis delta, with top line data expected first from ECLIPSE 1 in the fourth quarter of this year followed by readouts from ECLIPSE 2 and ECLIPSE 3 in the first quarter of 2027.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $75,761 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- de Verneuil VaninaSale
3 Nov 2026, EVP, General Counsel, Corp Secretary
- Shares
- 2,407
- Price
- $11.10
- Value
- $26,718
- de Verneuil VaninaSale
2 Nov 2026, EVP, General Counsel, Corp Secretary
- Shares
- 1,343
- Price
- $11.33
- Value
- $15,222
- Napolitano JanetSale
1 Jun 2026, Board
- Shares
- 3,200
- Price
- $9.45
- Value
- $30,240
Show 1 more
- Sabatini BrentSale
1 Jun 2026, SVP, Chief Accounting Officer
- Shares
- 379
- Price
- $9.45
- Value
- $3,582
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Vir Biotechnology
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 52
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- BiohavenBHVN $2.29B43
- Replimune GroupREPL $2.29B43
- SepternaSEPN $2.27B48
- ImmunomeIMNM $2.25B37
- Recursion PharmaceuticalsRXRX $2.24B39
- Maze TherapeuticsMAZE $2.24B46
- Vera TherapeuticsVERA $2.2B36
- Alamar BiosciencesALMR $2.2B47
ETFs that hold Vir Biotechnology
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 0.97% | 0.50% | €127.06M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.14% | 0.40% | €1.49B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.12% | 0.35% | €1.21B |
Show 5 more
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.09% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.07% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.06% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.06% | 0.30% | €4.22B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 28 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.